EPISODE · Mar 12, 2026 · 15 MIN
The AI Reckoning — Episode 4: Who Wins
from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group
Three competitive strategies. A $135.7 billion Chineseout-licensing signal. Three diverging regulatory frameworks. We pull together everything from the series into a practical framework: which companies arepositioned to win, which strategic models carry the most risk, and what every pharma professional should be doing right now.Substack: https://thepharmacloseout.substack.comLinkedin: www.linkedin.com/company/the-pharma-closeout#pharma, #AI strategy, #competitive advantage, #China pharma, #cross-border licensing, #FDA, #EMA, #NMPA, #regulatory divergence, #Eli Lilly, #Recursion, #GSK, #build vs buy
What this episode covers
Three competitive strategies. A $135.7 billion Chineseout-licensing signal. Three diverging regulatory frameworks. We pull together everything from the series into a practical framework: which companies arepositioned to win, which strategic models carry the most risk, and what every pharma professional should be doing right now.Substack: https://thepharmacloseout.substack.comLinkedin: www.linkedin.com/company/the-pharma-closeout#pharma, #AI strategy, #competitive advantage, #China pharma, #cross-border licensing, #FDA, #EMA, #NMPA, #regulatory divergence, #Eli Lilly, #Recursion, #GSK, #build vs buy
NOW PLAYING
The AI Reckoning — Episode 4: Who Wins
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m